Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8376895 | 0.87 | CYP2D6 (0.43) | TGFBR1ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL12642676 | 0.86 | TGFBR1 (0.39) | TGFBR1ALDH1A1MEN1KMT2ARXFP1 | |
| SCHEMBL16097 | 0.86 | TGFBR1 (0.39) | TGFBR1ALDH1A1MEN1KMT2ARXFP1 | |
| SCHEMBL4960192 | 0.84 | TGFBR1 (0.38) | TGFBR1ALDH1A1MEN1KMT2ARXFP1 | |
| Propylene Glycol SCHEMBL28248623 | 0.81 | TGFBR1 (0.44) | TGFBR1ALDH1A1RXFP1 | |
| Lactic Acid SCHEMBL341018 | 0.79 | TGFBR1 (0.43) | TGFBR1ALDH1A1MEN1KMT2ARXFP1 | |
| SCHEMBL1679408 | 0.77 | TGFBR1 (0.32) | TGFBR1 | |
| SCHEMBL8373364 | 0.77 | TGFBR1 (0.40) | TGFBR1ALDH1A1MEN1KMT2ARXFP1 | |
| Glycine SCHEMBL1564191 | 0.76 | TGFBR1 (0.37) | TGFBR1ALDH1A1MEN1KMT2ARXFP1 | |
| SCHEMBL8379994 | 0.76 | MCL1 (0.39) | TGFBR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731148-B1 | Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer | SYNTA PHARMACEUTICALS CORP (US) | 2011-11-16 | — | — | EP | claimed |
| US-20100068174-A1 | COMBINATION WITH BIS (THIOHYDRAZIDE AMIDES) FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP. | 2010-03-18 | — | — | US | claimed |
| EP-2061430-A2 | BIS (THIOHYDRAZIDE AMIDES) FORMULATION | Synta Pharmaceuticals Corporation (US) | 2009-05-27 | — | — | EP | claimed |
| US-20080214655-A1 | Paclitaxel enhancer compounds | SYNTA PHARMACEUTICALS CORP. | 2008-09-04 | — | — | US | claimed |
| WO-2008033300-A2 | BIS (THIOHYDRAZIDE AMIDES) FORMULATION | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1406869-B1 | TAXOL ENHANCER COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-13 | — | — | EP | claimed |
| US-20060116374-A1 | substituted bis/thiohydrazide amide compound; synergistic effect with taxol or taxotere, anticancer agents, side effect reduction | KOYA KEIZO | 2006-06-01 | — | — | US | claimed |
| US-7037940-B2 | Taxol enhancer compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-02 | — | — | US | claimed |
| US-7001923-B2 | substituted bis/thiohydrazide amide compound; synergistic effect with taxol or taxotere, anticancer agents, side effect reduction | SYNTA PHARMACEUTICALS CORP. (US) | 2006-02-21 | — | — | US | claimed |
| EP-1414792-A1 | FLUORO LINKERS AND THEIR USE AS LINKERS FOR ENZYME-ACTIVATED DRUG CONJUGATES | Pharmacia Italia S.p.A. (IT) | 2004-05-06 | — | — | EP | claimed |
| WO-2002007770-A2 | POLYMERIC CONJUGATES OF ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2002-01-31 | — | — | WO | claimed |
| US-6328953-B1 | AS ANTITUMOR AGENT AND REDUCED TOXICITY | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-12-11 | — | — | US | claimed |
| EP-1019090-A1 | POLYMERIC DERIVATIVES OF CAMPTOTHECINS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-07-19 | — | — | EP | claimed |
| EP-0944400-A1 | BIOACTIVE DERIVATIVES OF CAMPTOTHECIN | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-09-29 | — | — | EP | claimed |
| WO-1999017805-A1 | BIOACTIVE DERIVATIVES OF CAMPTOTHECIN | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-04-15 | — | — | WO | claimed |
| WO-1999017804-A1 | POLYMERIC DERIVATIVES OF CAMPTOTHECINS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-04-15 | — | — | WO | claimed |
| US-5773522-A | PRODRUGS FOR TREATMENT OF TUMORS | PHARMACIA S.P.A. (IT) | 1998-06-30 | — | — | US | claimed |
| US-5719265-A | ANTITUMOR AGENTS WITH IMPROVED WATER SOLUBILITY AND REDUCED TOXICITY | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-02-17 | — | — | US | claimed |
| EP-0673258-A1 | POLYMER-BOUND CAMPTOTHECIN DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1995-09-27 | — | — | EP | claimed |
| WO-1995010304-A1 | POLYMER-BOUND CAMPTOTHECIN DERIVATIVES | PHARMACIA S.P.A (IT) | 1995-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068174-A1 | COMBINATION WITH BIS (THIOHYDRAZIDE AMIDES) FOR TREATING CANCER | TP53, PDCD1, CD274 | TGFBR1 1438/4885ALDH1A1 188/4885LIPG 3856/4885 |
| US-20080214655-A1 | Paclitaxel enhancer compounds | ABCC8, FOXM1, C9 | TGFBR1 1110/4885ALDH1A1 1781/4885LIPG 2628/4885 |
| US-20060116374-A1 | substituted bis/thiohydrazide amide compound; synergistic effect with taxol or taxotere, anticancer agents, side effect reduction | TUBB8, TUBB, TUBA8 | TGFBR1 140/4885ALDH1A1 1811/4885LIPG 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.